GH Relative Valuation
GH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GH is overvalued; if below, it's undervalued.
Historical Valuation
Guardant Health Inc (GH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -20.08. The fair price of Guardant Health Inc (GH) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 108.52 USD , Guardant Health Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：108.52
Fair
Undervalued
-66.36
PE
1Y
3Y
5Y
Trailing
Forward
-92.09
EV/EBITDA
Guardant Health Inc. (GH) has a current EV/EBITDA of -92.09. The 5-year average EV/EBITDA is -22.07. The thresholds are as follows: Strongly Undervalued below -54.37, Undervalued between -54.37 and -38.22, Fairly Valued between -5.92 and -38.22, Overvalued between -5.92 and 10.23, and Strongly Overvalued above 10.23. The current Forward EV/EBITDA of -92.09 falls within the Strongly Undervalued range.
-38.85
EV/EBIT
Guardant Health Inc. (GH) has a current EV/EBIT of -38.85. The 5-year average EV/EBIT is -15.86. The thresholds are as follows: Strongly Undervalued below -37.29, Undervalued between -37.29 and -26.57, Fairly Valued between -5.14 and -26.57, Overvalued between -5.14 and 5.58, and Strongly Overvalued above 5.58. The current Forward EV/EBIT of -38.85 falls within the Strongly Undervalued range.
11.82
PS
Guardant Health Inc. (GH) has a current PS of 11.82. The 5-year average PS is 12.38. The thresholds are as follows: Strongly Undervalued below -10.03, Undervalued between -10.03 and 1.17, Fairly Valued between 23.59 and 1.17, Overvalued between 23.59 and 34.79, and Strongly Overvalued above 34.79. The current Forward PS of 11.82 falls within the Historic Trend Line -Fairly Valued range.
-103.11
P/OCF
Guardant Health Inc. (GH) has a current P/OCF of -103.11. The 5-year average P/OCF is -26.70. The thresholds are as follows: Strongly Undervalued below -69.71, Undervalued between -69.71 and -48.21, Fairly Valued between -5.19 and -48.21, Overvalued between -5.19 and 16.32, and Strongly Overvalued above 16.32. The current Forward P/OCF of -103.11 falls within the Strongly Undervalued range.
-63.08
P/FCF
Guardant Health Inc. (GH) has a current P/FCF of -63.08. The 5-year average P/FCF is -22.18. The thresholds are as follows: Strongly Undervalued below -56.69, Undervalued between -56.69 and -39.43, Fairly Valued between -4.92 and -39.43, Overvalued between -4.92 and 12.34, and Strongly Overvalued above 12.34. The current Forward P/FCF of -63.08 falls within the Strongly Undervalued range.
Guardant Health Inc (GH) has a current Price-to-Book (P/B) ratio of -38.27. Compared to its 3-year average P/B ratio of -238.84 , the current P/B ratio is approximately -83.98% higher. Relative to its 5-year average P/B ratio of -136.61, the current P/B ratio is about -71.99% higher. Guardant Health Inc (GH) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -9.19%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.97% , the current FCF yield is about -100.00% lower.
-38.27
P/B
Median3y
-238.84
Median5y
-136.61
-1.92
FCF Yield
Median3y
-9.19
Median5y
-6.97
Competitors Valuation Multiple
The average P/S ratio for GH's competitors is 0.59, providing a benchmark for relative valuation. Guardant Health Inc Corp (GH) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 38.50%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of GH increased by 255.22% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -9.53 to -33.78.
The secondary factor is the Revenue Growth, contributed 38.50%to the performance.
Overall, the performance of GH in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Guardant Health Inc (GH) currently overvalued or undervalued?
What is Guardant Health Inc (GH) fair value?
How does GH's valuation metrics compare to the industry average?
What is the current P/B ratio for Guardant Health Inc (GH) as of Dec 05 2025?
What is the current FCF Yield for Guardant Health Inc (GH) as of Dec 05 2025?
What is the current Forward P/E ratio for Guardant Health Inc (GH) as of Dec 05 2025?